File Download
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Nucleic acid aptamers against aggrecanases: a novel method for Degenerative Disc Disease Therapy
Title | Nucleic acid aptamers against aggrecanases: a novel method for Degenerative Disc Disease Therapy |
---|---|
Authors | |
Keywords | Aptamers degenerative disc disease ADAMTS-4 ADAMTS-5 SELEX |
Issue Date | 2013 |
Publisher | Global Biotechnology Congress. |
Citation | The 2013 Global Biotechnology Congress (GBC), Boston, MA., 3-6 June 2013. In Abstract Book, 2013, p. 161, abstract no. PO-48 How to Cite? |
Abstract | Aptamers are short, single-stranded oligonucleotides, which bind to their targets through 3D conformational
complementarity. Aptamers are frequently called 'chemical antibodies' because of their high specificity and affinity.
More than 20 aptamers for the treatment of various diseases are evaluated in clinical trials. Role of intervertebral disc is
to absorb shock and transmit load, allowing the spine to bend and move. Disc degeneration may cause serious low back
pain and affect daily life. Aggrecanases ADAMTS-4 and -5 are critical proteins involved in the development of
degenerative disc disease (DDD) and osteoarthritis. They have been used as targets for inhibitor selection against DDD
in recent studies both in vitro and in silico. Small molecules targeted on catalytic domain of aggrecanases have been
developed but have broad inhibitory activity which may cause serious side effects. Nucleic acid aptamers can potentially
solve this problem. Recent studies on aggrecanases have also been restrained by the low expression level and low
solubility of the catalytic domain. Our studies have developed new ways to express, refold and purify human
ADAMTS-4 and ADAMTS-5. ADAMTS-4 and ADAMTS-5 catalytic domain incorporating with disintegrin domain
and thrombospondin motif are expressed and purified from E. coli with high yield for the first time. Specific aptamers
will then be tailor selected against each aggrecanase through a process called Systematic Evolution of Ligands by
Exponential enrichment (SELEX). Selected aptamers will then be characterized and evaluated as a foundation for further
DDD therapeutic development. |
Description | Poster Presentation Track: Pharmaceutical Biotechnology |
Persistent Identifier | http://hdl.handle.net/10722/186628 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yu, Y | en_US |
dc.contributor.author | Tanner, JA | en_US |
dc.date.accessioned | 2013-08-20T12:15:37Z | - |
dc.date.available | 2013-08-20T12:15:37Z | - |
dc.date.issued | 2013 | en_US |
dc.identifier.citation | The 2013 Global Biotechnology Congress (GBC), Boston, MA., 3-6 June 2013. In Abstract Book, 2013, p. 161, abstract no. PO-48 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/186628 | - |
dc.description | Poster Presentation | - |
dc.description | Track: Pharmaceutical Biotechnology | - |
dc.description.abstract | Aptamers are short, single-stranded oligonucleotides, which bind to their targets through 3D conformational complementarity. Aptamers are frequently called 'chemical antibodies' because of their high specificity and affinity. More than 20 aptamers for the treatment of various diseases are evaluated in clinical trials. Role of intervertebral disc is to absorb shock and transmit load, allowing the spine to bend and move. Disc degeneration may cause serious low back pain and affect daily life. Aggrecanases ADAMTS-4 and -5 are critical proteins involved in the development of degenerative disc disease (DDD) and osteoarthritis. They have been used as targets for inhibitor selection against DDD in recent studies both in vitro and in silico. Small molecules targeted on catalytic domain of aggrecanases have been developed but have broad inhibitory activity which may cause serious side effects. Nucleic acid aptamers can potentially solve this problem. Recent studies on aggrecanases have also been restrained by the low expression level and low solubility of the catalytic domain. Our studies have developed new ways to express, refold and purify human ADAMTS-4 and ADAMTS-5. ADAMTS-4 and ADAMTS-5 catalytic domain incorporating with disintegrin domain and thrombospondin motif are expressed and purified from E. coli with high yield for the first time. Specific aptamers will then be tailor selected against each aggrecanase through a process called Systematic Evolution of Ligands by Exponential enrichment (SELEX). Selected aptamers will then be characterized and evaluated as a foundation for further DDD therapeutic development. | - |
dc.language | eng | en_US |
dc.publisher | Global Biotechnology Congress. | - |
dc.relation.ispartof | Global Biotechnology Congress, GBC 2013 | en_US |
dc.subject | Aptamers | - |
dc.subject | degenerative disc disease | - |
dc.subject | ADAMTS-4 | - |
dc.subject | ADAMTS-5 | - |
dc.subject | SELEX | - |
dc.title | Nucleic acid aptamers against aggrecanases: a novel method for Degenerative Disc Disease Therapy | en_US |
dc.type | Conference_Paper | en_US |
dc.identifier.email | Tanner, JA: jatanner@hku.hk | en_US |
dc.identifier.authority | Tanner, JA=rp00495 | en_US |
dc.description.nature | published_or_final_version | - |
dc.identifier.hkuros | 217917 | en_US |
dc.identifier.spage | 161, abstract no. PO-48 | - |
dc.identifier.epage | 161, abstract no. PO-48 | - |
dc.publisher.place | United States | - |